Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Shares Outstanding (Diluted Average): 2021-2025

Historic Shares Outstanding (Diluted Average) for Arcturus Therapeutics Holdings (ARCT) over the last 5 years, with Sep 2025 value amounting to $27.2 million.

  • Arcturus Therapeutics Holdings' Shares Outstanding (Diluted Average) rose 0.47% to $27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.2 million, marking a year-over-year increase of 0.47%. This contributed to the annual value of $27.0 million for FY2024, which is 1.40% up from last year.
  • Per Arcturus Therapeutics Holdings' latest filing, its Shares Outstanding (Diluted Average) stood at $27.2 million for Q3 2025, which was up 0.22% from $27.1 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Shares Outstanding (Diluted Average) registered a high of $27.2 million during Q3 2025, and its lowest value of $26,376 during Q1 2022.
  • In the last 3 years, Arcturus Therapeutics Holdings' Shares Outstanding (Diluted Average) had a median value of $27.0 million in 2024 and averaged $26.9 million.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Shares Outstanding (Diluted Average) slumped by 99.90% in 2022, and later soared by 102,830.69% in 2023.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Shares Outstanding (Diluted Average) (Quarterly) stood at $26.3 million in 2021, then climbed by 2.95% to $27.1 million in 2022, then fell by 1.72% to $26.6 million in 2023, then climbed by 1.40% to $27.0 million in 2024, then grew by 0.47% to $27.2 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $27.2 million in Q3 2025, compared to $27.1 million in Q2 2025 and $27.1 million in Q1 2025.